Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.65 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.64 |
| ▸ | ACLY | P53396 | 3/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10593438 | 0.94 | KMO (0.62) | KMOOXER1ACLYALOX5EPHX2 | |
| SCHEMBL1576323 | 0.91 | KMO (0.78) | KMOOXER1ACLYHTR2AHTR2C | |
| SCHEMBL27587769 | 0.84 | ALOX5 (0.50) | KMOOXER1ACLYALOX5EPHX2 | |
| SCHEMBL416378 | 0.82 | ALOX5 (0.49) | KMOOXER1ALOX5EPHX2MCL1 | |
| SCHEMBL418370 | 0.82 | P2RX7 (0.50) | KMOOXER1ALOX5EPHX2MCL1 | |
| SCHEMBL9702533 | 0.81 | KMT2A (0.60) | KMOOXER1ACLYHTR2AHTR2C | |
| SCHEMBL13980991 | 0.81 | KMO (0.58) | KMOOXER1ACLYHTR2AHTR2C | |
| SCHEMBL10203773 | 0.79 | KMO (0.57) | KMOOXER1ACLYHTR2AHTR2C | |
| SCHEMBL413159 | 0.79 | FFAR4 (0.55) | KMOOXER1ALOX5EPHX2MCL1 | |
| SCHEMBL1967792 | 0.78 | CDK4 (0.68) | KMOCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | KMO 3225/4885OXER1 4248/4885ACLY 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.